Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shalom Haggiag

Showing results (1-10 of 68) with videos related to

Pageof 7
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 8, 2024
Late-onset multiple sclerosis from a different angleLuca Prosperini, Shalom Haggiag
Therapeutic Advances in Neurological Disorders|November 15, 2013
Efficacy and safety of laquinimod in multiple sclerosis: current statusShalom Haggiag, Serena Ruggieri, Claudio Gasperini
Expert Opinion on Investigational Drugs|July 17, 2013
Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodiesClaudio Gasperini, Shalom Haggiag, Serena Ruggieri
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|October 24, 2018
Electrophysiological abnormalities in iatrogenic botulism: Two case reports and review of the literatureLuca Leonardi, Shalom Haggiag, Antonio Petrucci, et al.
Multiple Sclerosis and Related Disorders|December 7, 2016
Extratemporal herpes encephalitis during natalizumab treatment: A case reportShalom Haggiag, Luca Prosperini, Simonetta Galgani, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 1, 2023
Dimethyl Fumarate or Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A Meta-analysis of Post-marketing StudiesLuca Prosperini, Shalom Haggiag, Serena Ruggieri, et al.
CNS Drugs|September 23, 2023
Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World StudiesLuca Prosperini, Shalom Haggiag, Serena Ruggieri, et al.
Journal of Neurology|July 19, 2018
Early transient asymptomatic neutropenia associated with alemtuzumab treatment in multiple sclerosis: a case reportSimonetta Galgani, Luca Prosperini, Shalom Haggiag, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 31, 2024
Disability patterns in multiple sclerosis: A meta-analysis on RAW and PIRA in the real-world contextLuca Prosperini, Serena Ruggieri, Shalom Haggiag, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 26, 2020
Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regressionLuca Prosperini, Shalom Haggiag, Carla Tortorella, et al.
Pageof 7

Showing results (1-10 of 68) with videos related to

Sort By:
Pageof 7
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 8, 2024
Late-onset multiple sclerosis from a different angleLuca Prosperini, Shalom Haggiag
Therapeutic Advances in Neurological Disorders|November 15, 2013
Efficacy and safety of laquinimod in multiple sclerosis: current statusShalom Haggiag, Serena Ruggieri, Claudio Gasperini
Expert Opinion on Investigational Drugs|July 17, 2013
Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodiesClaudio Gasperini, Shalom Haggiag, Serena Ruggieri
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|October 24, 2018
Electrophysiological abnormalities in iatrogenic botulism: Two case reports and review of the literatureLuca Leonardi, Shalom Haggiag, Antonio Petrucci, et al.
Multiple Sclerosis and Related Disorders|December 7, 2016
Extratemporal herpes encephalitis during natalizumab treatment: A case reportShalom Haggiag, Luca Prosperini, Simonetta Galgani, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 1, 2023
Dimethyl Fumarate or Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A Meta-analysis of Post-marketing StudiesLuca Prosperini, Shalom Haggiag, Serena Ruggieri, et al.
CNS Drugs|September 23, 2023
Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World StudiesLuca Prosperini, Shalom Haggiag, Serena Ruggieri, et al.
Journal of Neurology|July 19, 2018
Early transient asymptomatic neutropenia associated with alemtuzumab treatment in multiple sclerosis: a case reportSimonetta Galgani, Luca Prosperini, Shalom Haggiag, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 31, 2024
Disability patterns in multiple sclerosis: A meta-analysis on RAW and PIRA in the real-world contextLuca Prosperini, Serena Ruggieri, Shalom Haggiag, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 26, 2020
Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regressionLuca Prosperini, Shalom Haggiag, Carla Tortorella, et al.
Pageof 7